March 4, 2020 / 3:11 PM / a month ago

BRIEF-Arch Biopartners Expands Dosing In Phase I Trial For Metablok To Increase Dose Range For Future Phase II Studies

March 4 (Reuters) - Arch Biopartners Inc:

* ARCH BIOPARTNERS EXPANDS DOSING IN PHASE I TRIAL FOR METABLOK TO INCREASE DOSE RANGE FOR FUTURE PHASE II STUDIES

* ARCH BIOPARTNERS- DOSING OF EIGHT ADDITIONAL VOLUNTEERS HAS BEGUN AND DOSING IS EXPECTED TO END DURING MARCH 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below